Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical alzheimer's disease: Insights into memory loss in MCI

Journal of Alzheimer's Disease

Volumn 23, Issue 2, 2011, Pages 257-269

  Aluise, Christopher D ^a,b   Robinson, Ren A S ^a,b   Cai, Jian ^c   Pierce, William M ^c   Markesbery, William R ^b   Butterfield, D Allan ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Alzheimer's disease; brain; mild cognitive impairment; oxidative stress; preclinical Alzheimer's; proteomics; redox proteomics; two dimensional gel electrophoresis

Indexed keywords

ALBUMIN; COPPER ZINC SUPEROXIDE DISMUTASE; ELONGATION FACTOR TU; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN 1; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRUVATE KINASE; UBIQUITIN CARBOXY TERMINAL HYDROLASE 1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMNESIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; INFERIOR PARIETAL LOBULE; MALE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEOMICS; SLOT BLOT HYBRIDIZATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 79951560784     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101083     Document Type: Article

References (61)

1. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194. (Pubitemid 39222988)
2. Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 359, 322-325.
3. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359, 325-327.
4. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, Tintner R, Frangione B, et al. (1992) Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258, 126-129.
5. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA (1998) Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 4, 827-831. (Pubitemid 28331025)
6. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009) Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801.
7. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW (1991) In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563, 311-314.
8. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27, 2866-2875. (Pubitemid 46438992)
9. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
10. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30, 1026-1036.
11. Iacono D, Markesbery WR, Gross M, Pletnikova O, Rudow G, Zandi P, Troncoso JC (2009) The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 73, 665-673.
12. GoldmanWP, Price JL, StorandtM,Grant EA,McKeelDWJr, Rubin EH, Morris JC (2001) Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 56, 361-367. (Pubitemid 32144148)
13. Aluise CD, Robinson RA, Beckett TL, Murphy MP, Cai J, Pierce WM, Markesbery WR, Butterfield DA (2010) Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis 39, 221-228.
14. West MJ, Kawas CH, Stewart WF, Rudow GL, Troncoso JC (2004) Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging 25, 1205-1212. (Pubitemid 39094023)
15. O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, Pletnikova O, Rudow G, Iacono D, Riudavets MA, Driscoll I, Price DL, Martin LJ, Troncoso JC (2009) Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J Alzheimers Dis 18, 665-675.
16. Lyubartseva G, Smith JL, Markesbery WR, Lovell MA (2010) Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol 20, 343-350.
17. Sultana R, Perluigi M, Butterfield DA (2009) Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 118, 131-150.
18. Thongboonkerd V, Luengpailin J, Cao J, Pierce WM, Cai J, Klein JB, Doyle RJ (2002) Fluoride exposure attenuates expression of Streptococcus pyogenes virulence factors. J Biol Chem 277, 16599-16605. (Pubitemid 34967677)
19. Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7, 548-554. (Pubitemid 33127140)
20. Butterfield DA, Poon HF, St Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22, 223-232.
21. Lovell MA, Markesbery WR (2007) Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res 85, 3036-3040. (Pubitemid 350057358)
22. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD (2005) Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58, 730-735. (Pubitemid 41552548)
23. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA (2008) Redox proteomic identification of 4-hydroxy-2- nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis 30, 107-120.
24. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Zhou XZ, Lu KP, Butterfield DA (2006) Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol Aging 27, 918-925.
25. Sultana R, Perluigi M, Newman SF, Pierce WM, Cini C, Coccia R, Butterfield A (2010) Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. Antioxid Redox Signal 12, 327-336.
26. Sultana R, Piroddi M, Galli F, Butterfield DA (2008) Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33, 2540-2546.
27. Smith MA, Perry G (1995) Free radical damage, iron, and Alzheimer's disease. J Neurol Sci 134(Suppl), 92-94.
28. Bradley MA, Markesbery WR, Lovell MA (2010) Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer's disease (PCAD). Free Radic Biol Med 48, 1570-1576.
29. Smith MA, Siedlak SL, Richey PL, Nagaraj RH, Elhammer A, Perry G (1996) Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. Brain Res 717, 99-108. (Pubitemid 26153441)
30. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N (1996) Oxidative damage in Alzheimer's. Nature 382, 120-121.
31. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR (2001) Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103, 373-383. (Pubitemid 32201924)
32. Castegna A, AksenovM, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinaserelated protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82, 1524-1532.
33. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33, 562-571. (Pubitemid 34874977)
34. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A 88, 10540-10543. (Pubitemid 21915871)
35. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA (2006) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 27, 1564-1576. (Pubitemid 44344840)
36. Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N, Perry G (1998) Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4- dinitrophenylhydrazine. J Histochem Cytochem 46, 731-735. (Pubitemid 28272207)
37. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, Sultana R (2006) Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 397, 170-173.
38. Opii WO, Joshi G, Head E, Milgram NW, Muggenburg BA, Klein JB, Pierce WM, Cotman CW, Butterfield DA (2008) Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging 29, 51-70. (Pubitemid 350102715)
39. Mastrogiacoma F, Lindsay JG, Bettendorff L, Rice J, Kish SJ (1996) Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. Ann Neurol 39, 592-598. (Pubitemid 26143597)
40. Sheu KF, Kim YT, Blass JP,Weksler ME (1985) An immunochemical study of the pyruvate dehydrogenase deficit in Alzheimer's disease brain. Ann Neurol 17, 444-449. (Pubitemid 15019982)
41. Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6, 78-87.
42. Schagger H, Ohm TG (1995) Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. Eur J Biochem 227, 916-921.
43. Chandrasekaran K, Hatanpaa K, Rapoport SI, Brady DR (1997) Decreased expression of nuclear and mitochondrial DNA-encoded genes of oxidative phosphorylation in association neocortex in Alzheimer disease. Brain Res Mol Brain Res 44, 99-104. (Pubitemid 27050865)
44. ReedTT, PierceWM,MarkesberyWR,ButterfieldDA(2009) Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res 1274, 66-76.
45. Takei N, Kondo J, Nagaike K, Ohsawa K, Kato K, Kohsaka S (1991) Neuronal survival factor from bovine brain is identical to neuron-specific enolase. J Neurochem 57, 1178-1184. (Pubitemid 21922739)
46. Hattori T, Ohsawa K, Mizuno Y, Kato K, Kohsaka S (1994) Synthetic peptide corresponding to 30 amino acids of the C-terminal of neuron-specific enolase promotes survival of neocortical neurons in culture. Biochem Biophys ResCommun 202, 25-30. (Pubitemid 24252560)
47. Hattori T, Takei N, Mizuno Y, Kato K, Kohsaka S (1995) Neurotrophic and neuroprotective effects of neuron-specific enolase on cultured neurons from embryonic rat brain. Neurosci Res 21, 191-198.
48. Aaronson RM, Graven KK, Tucci M, McDonald RJ, Farber HW (1995) Non-neuronal enolase is an endothelial hypoxic stress protein. J Biol Chem 270, 27752-27757.
49. Ray R, Miller DM (1991) Cloning and characterization of a human c-myc promoter-binding protein. Mol Cell Biol 11, 2154-2161. (Pubitemid 21895587)
50. Subramanian A, Miller DM (2000) Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem 275, 5958-5965. (Pubitemid 30115245)
51. Nakajima K, Hamanoue M, Takemoto N, Hattori T, Kato K, Kohsaka S (1994) Plasminogen binds specifically to alphaenolase on rat neuronal plasma membrane. J Neurochem 63, 2048-2057. (Pubitemid 24369977)
52. PancholiV, FischettiVA(1998) Alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem 273, 14503-14515. (Pubitemid 28319172)
53. Parnetti L, Palumbo B, Cardinali L, Loreti F, Chionne F, Cecchetti R, Senin U (1995) Cerebrospinal fluid neuronspecific enolase in Alzheimer's disease and vascular dementia. Neurosci Lett 183, 43-45.
54. Dotti CG, Galvan C, LedesmaMD(2004) Plasmin deficiency in Alzheimer's disease brains: causal or casual? Neurodegener Dis 1, 205-212. (Pubitemid 39551798)
55. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 279, 13256-13264. (Pubitemid 38445905)
56. Zhang D, Li J, Costa M, Gao J, Huang C. JNK1 mediates degradation HIF-1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70. Cancer Res 70, 813-823.
57. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L (1990) Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 81, 323-326. (Pubitemid 20174132)
58. George AJ, Holsinger RM, McLean CA, Tan SS, Scott HS, Cardamone T, Cappai R, Masters CL, Li QX (2006) Decreased phosphatidylethanolamine binding protein expression correlates with Abeta accumulation in the Tg2576 mouse model of Alzheimer's disease. Neurobiol Aging 27, 614-623. (Pubitemid 43290530)
59. Maki M, Matsukawa N, Yuasa H, Otsuka Y, Yamamoto T, Akatsu H, Okamoto T, Ueda R, Ojika K (2002) Decreased expression of hippocampal cholinergic neurostimulating peptide precursor protein mRNA in the hippocampus in Alzheimer disease. J Neuropathol Exp Neurol 61, 176-185. (Pubitemid 34127101)
60. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC (2001) Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 58, 1395-1402. (Pubitemid 32845990)
61. Gomez-Isla T, Price JL, McKeel DWJr, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16, 4491-4500. (Pubitemid 26243044)